Evolus’ Q2 Playbook: Profhilo Expansion, Europe’s Estyme Push and a Raised Revenue Outlook

Executive snapshot

Evolus, Inc. (ticker: EOLS) delivered its second-quarter 2026 results with a clear tether to growth beyond cosmetics-in-a-basket hype. The company posted revenue of $84.1 million for the quarter, up 21% year over year, while reporting a GAAP operating loss of $4.5 million and a positive adjusted EBITDA of $4.7 million. Management used the moment to lift the full-year revenue forecast to a range of $330 million to $337 million and to tighten a non-GAAP operating expense band to $212 million to $216 million. In a press release dense with margin talk, Evolus reaffirmed an outlook for low- to mid-single-digit Adjusted EBITDA margins in 2026, positioning the quarter as more than a temporary momentum swing.

Note the non-GAAP focus: there is no explicit EPS figure shared, a common practice for Evolus’ disclosures. Analysts will likely translate the operating and EBITDA signals into an implied earnings-per-share framework, but the headline remains revenue growth and operating leverage as the company scales its injectable portfolio.

Second-quarter financials at a glance

• Net revenue: $84.1 million, +21% YoY
• GAAP operating loss: $4.5 million
• Adjusted EBITDA: $4.7 million (positive for the third straight quarter)
• Full-year 2026 revenue forecast: raised to $330–$337 million
• Adjusted gross margin guidance: 67.0%–67.5%
• Non-GAAP operating expenses: $212–$216 million
• EBITDA margin outlook: reaffirmed in the low- to mid-single digits for 2026

The numbers underscore a company leaning into higher revenue capture while maintaining discipline on costs—an important signal for a sector whose margins hinge on portfolio mix and international expansion. For readers watching “EPS consensus” or “earnings surprise,” Evolus’ emphasis on adjusted EBITDA and guided margins will be the more informative yardstick this quarter.

Strategic momentum: portfolio expansion and licensing

The quarter’s narrative centers on growth channels beyond Jeuveau and Evolysse. Evolus highlighted an expanded global injectable portfolio through the addition of Profhilo, a leading skin-quality injectable in Europe, and the broader “Estyme” lineup of HA gels across Europe. Management framed this as the third vertical in the U.S. injectable portfolio, paired with plans for rapid commercialization in 2028 for related HA assets.

In the U.S., Evolus extended its exclusive licensing agreement with IBSA to develop and commercialize Profhilo, signaling a strategic pivot toward premium HA assets as a complement to its neurotoxin and filler lines. The company also noted the expansion of licensing with Symatese to Canada, Australia, and New Zealand—the Canada-Australia-New Zealand corridor has long been a proving ground for cross-border growth and regulatory navigation. Management positions these moves as a path to healthier peak revenue trajectories and diversified risk across markets.

From the top: CEO commentary and commentary on the path forward

“The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau and accelerating adoption of Evolysse,” said David Moatazedi, President and Chief Executive Officer of Evolus. “We delivered another quarter of consistent execution, highlighted by 21% revenue growth and a third consecutive quarter of positive Adjusted EBITDA, representing a $12.6 million improvement over the prior-year period. Based on our first-half results, we are raising our full-year 2026 financial outlook while continuing to invest in strategic opportunities that strengthen our long-term growth profile.”

Moatazedi’s tone pairs confidence with a recognition that the next phase hinges on converting portfolio momentum into sustained profitability and deeper international penetration. The emphasis on Profhilo and Estyme shows Evolus betting on premium materials and regional leadership to compete as a diversified aesthetics platform, rather than a one-off brand owner.

Portfolio expansion: the international horizon and pipeline

Beyond Jeuveau, the Estyme collection across Europe could redefine Evolus’ price-to-value narrative in the near term. The licensing expansion with Symatese to Canada, Australia, and New Zealand is not merely a geography move; it’s a test of go-to-market orchestration across regulatory regimes and reimbursement environments. The company also alludes to ongoing commercialization efforts in 2028 for new acne-haunted HA gels, signaling a longer-term revenue ramp that could help bridge the gap between current profitability and the company’s aspirational margins.

Outlook and the optionality in 2028

Evolus reaffirmed a bold 2028 long-term financial outlook: total net revenue between $450 million and $500 million, with Adjusted EBITDA margins of 13% to 15%. That implies a multi-year expansion path predicated on portfolio mix shifts, international scaling, and continued adoption of premium HA therapies alongside neurotoxins. Investors should note that such a long runway comes with execution risk—regulatory clarity, competitive response, and the speed of new product commercialization will be the levers that determine whether the 2028 target remains within reach.

Implications for Evolus and its sector peers

The quarter places Evolus at an interesting inflection: a consumer-healthcare vector seeking to blend a strong domestic base with international expansion and premium asset licensing. For sector peers, the narrative reinforces the importance of a diversified product portfolio and cross-border collaborations as a hedge against any single market headwinds. Watch for a possible uptick in licensing activity and strategic partnerships in the injectable aesthetics space, as companies seek to de-risk dependence on a single platform or region.

The plastics-and-beauty mix is increasingly about pipeline velocity, not merely quarterly receipts. If Evolus can translate the 2026 revenue guidance raise into faster clinical and regulatory approvals for Estyme and Profhilo in new markets, peers may feel pressure to accelerate their own international licenses and product introductions. Conversely, delays in any piece of this plan—especially regulatory or supply-chain constraints—could compress margin expansion and push some investors back toward the more predictable but slower-growth incumbents.

Takeaways for investors and readers

• The Q2 results reinforce a growth narrative centered on portfolio diversification, not a single-blockbuster product.
• Revenue growth is translating into a more favorable outlook for 2026, though real profitability hinges on managing operating expenses and gross margins as the product mix broadens.
• Strategic deals—Profhilo licensing, Estyme expansion, and Symatese partnerships—are the byproducts of Evolus’ ambition to become a global injectable aesthetics platform.
• For EPS-centric readers, the absence of a disclosed EPS figure means the stock’s performance will likely hinge on EBITDA-driven valuation and the potential earnings-per-share implication from non-GAAP adjustments rather than a traditional beat/miss narrative.
• Watching the trajectory of the 2028 revenue target and margin range will be essential to gauge whether the company’s long-range plan is on track, or if execution mismatches will warrant a reassessment.

Conclusion: a bet on a diversified, international growth curve

Evolus’ Q2 2026 results read like a disciplined expansion plan more than a one-quarter miracle. The company is leaning into a broader portfolio, elevated by Profhilo and Estyme, and is betting on international expansion as a meaningful driver of revenue growth. The path forward—delivering on raised revenue forecasts, expanding gross margins, and achieving the 2028 targets—will determine whether the next few quarters become a steady drumbeat of progress or a test of patience for investors awaiting a clearer EPS narrative. In the world of injectable aesthetics, Evolus appears to be building a platform story rather than a single product equity story—a distinction that could shape sector dynamics in the years to come.